Skip to content
AnalystLens

Halozyme Therapeutics Quarterly Report for Q1 Ended Mar 31, 2026

Filing Date
Filed May 11, 2026
Period End
March 31, 2026
Security
HALO
One revenue dollarkept$0.40
In the record · 2016–202610-K1110-Q338-K141

HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Material agreement8-K · Nov ’19Nov ’19
  3. Leadership change8-K · Feb ’23Feb ’23
  4. Leadership change8-K · Mar ’25Mar ’25

Summary

Summary of the 10-Q filed May 11, 2026. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics, Inc. reported first-quarter 2026 total revenues of $376.7 milliona, up from $264.9 million a year earlier, driven primarily by royalties of $240.7 million (versus $168.2 million) and product sales, net of $130.4 million (versus $78.0 million).

Net income rose to $150.0 millionb, or $1.22 per diluted share, compared with $118.1 million, or $0.93 per diluted share, in the prior-year quarter. Royalty growth was led by DARZALEX, VYVGART Hytrulo and Phesgo, and bulk rHuPH20 sales increased to $73.5 million from $27.0 million. Operating expenses rose to $192.2 million from $123.3 million, reflecting cost of sales, amortization tied to the Elektrofi acquisition, higher research and development and higher SG&A.

At March 31, 2026, cash and cash equivalents were $309.7 millionc and cash, cash equivalents and marketable securities totaled $318.6 million. Total debt principal was $2.18 billion across the 2027, 2028, 2031 and 2032 convertible notes, and the $750 million revolving credit facility was undrawn. Net cash provided by operating activities was $180.1 million.

The company stated that its current cash and marketable securities will be sufficient to fund operations for at least the next 12 months. Subsequent to quarter end, in May 2026, the Board authorized a new share repurchase program of up to $1 billiond through December 31, 2028, with an expectation of buying back at least $400 million of shares in 2026. The filing also discloses new collaborations, including GSK, Oruka and Vertex, and notes that a partner is evaluating a potential target return by September 2026, which could trigger a material interim impairment charge to intangibles and/or goodwill.

Key Highlights

  1. Total revenues were $376.7 million, up from $264.9 million in Q1 2025, with royalties of $240.7 million and product sales, net of $130.4 million.
  2. Net income was $150.0 million, or $1.22 per diluted share, versus $118.1 million, or $0.93 per diluted share, a year earlier.
  3. Bulk rHuPH20 sales rose to $73.5 million from $27.0 million, and royalty growth was led by DARZALEX, VYVGART Hytrulo and Phesgo.
  4. Operating expenses increased to $192.2 million from $123.3 million, including higher cost of sales, amortization of intangibles, research and development and SG&A.
  5. Cash, cash equivalents and marketable securities totaled $318.6 million at March 31, 2026, against total convertible note principal of $2.18 billion; the $750 million revolver was undrawn.
  6. In May 2026, the Board authorized a new buyback of up to $1 billion through December 31, 2028, with at least $400 million expected in 2026; no repurchases were made in Q1 2026.
  7. A partner is evaluating a potential return of a Hypercon target, with a decision expected by September 2026; a return could trigger a material interim impairment of intangibles and/or goodwill.

Follow one dollar

Of each $1.00 of revenue in Q1 FY2026, Halozyme Therapeutics kept $0.40.

  1. Revenue$376.7M100.0%
  2. Cost of revenue−$79.2M21.0%
  3. Gross profit$297.5M79.0%
  4. Operating costs−$113.0M30.0%
  5. Operating income$184.5M49.0%
  6. Interest, other & tax−$34.5M9.1%
  7. Net income$150.0M39.8%
Computed from 10-QQ1 FY2026filed May 11, 2026Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

Q1 FY2026 against Q1 FY2025

Line itemQ1 FY2026Q1 FY2025Change
Revenue$376.71M$264.86M+42.2%
Cost of Revenue$79.24M$48.40M+63.7%
Gross Profit$297.47M$216.46M+37.4%
R&D Expenses$25.56M$14.80M+72.7%
SG&A Expenses$57.88M$42.36M+36.6%
Operating Expenses$192.19M$123.33M+55.8%
Operating Income$184.52M$141.53M+30.4%
Net Income$150.05M$118.09M+27.1%
EPS (Basic)$1.27$0.96+32.3%
EPS (Diluted)$1.22$0.93+31.2%
Shares Outstanding (Basic)118.14M123.22M−4.1%
Shares Outstanding (Diluted)122.88M126.64M−3.0%

Frequently Asked Questions

  1. How did Halozyme's revenue and profitability change in the first quarter of 2026?

    Total revenues increased to $376.7 million from $264.9 million, and net income increased to $150.0 million from $118.1 million. Diluted EPS was $1.22 compared with $0.93 a year earlier. Royalties of $240.7 million and product sales of $130.4 million drove the growth, partly offset by higher operating expenses of $192.2 million.

  2. What is the company's liquidity position?

    Cash and cash equivalents were $309.7 million at March 31, 2026, and cash, cash equivalents and marketable securities totaled $318.6 million. Net cash provided by operating activities was $180.1 million in the quarter. The company states these resources are sufficient to fund operations for at least the next 12 months, and its $750 million revolving credit facility was undrawn.

  3. What is the company's debt profile?

    Total principal of convertible notes was $2.18 billion, comprising the 2027, 2028, 2031 and 2032 Convertible Notes. The filing states that the company was in compliance with all covenants as of March 31, 2026. The 2031 and 2032 notes are convertible only under specified conditions, and the company may settle conversions in cash, shares or a combination.

  4. What capital return and business developments were announced after quarter end?

    In May 2026, the Board authorized a new program to repurchase up to $1 billion of common stock by December 31, 2028, with at least $400 million expected in 2026. The company also announced new ENHANZE and Hypercon agreements with GSK, Oruka and Vertex, and argenx received FDA approval of a supplemental BLA for VYVGART Hytrulo in generalized myasthenia gravis.

  5. What risks does the filing highlight regarding acquired intangibles?

    A partner is evaluating a potential return of a target, with a decision expected by September 2026. If the partner returns the target without nominating an alternative with similar future cash flows, the company would need to evaluate its Elektrofi customer relationship intangibles, other intangibles and goodwill. The filing states this could result in a material interim impairment charge. Net intangible assets were $951.9 million and goodwill was $582.3 million at March 31, 2026.